[go: up one dir, main page]

AR052804A1 - Uso de inhibidores de mek en el tratamiento del crecimiento celular anormal - Google Patents

Uso de inhibidores de mek en el tratamiento del crecimiento celular anormal

Info

Publication number
AR052804A1
AR052804A1 ARP050105154A ARP050105154A AR052804A1 AR 052804 A1 AR052804 A1 AR 052804A1 AR P050105154 A ARP050105154 A AR P050105154A AR P050105154 A ARP050105154 A AR P050105154A AR 052804 A1 AR052804 A1 AR 052804A1
Authority
AR
Argentina
Prior art keywords
cell growth
abnormal cell
treatment
mek inhibitors
phenylamino
Prior art date
Application number
ARP050105154A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR052804A1 publication Critical patent/AR052804A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Uso del compuesto N-[(R)-2,3-dihidroxi-propoxi]-3,4-difluoro-2-(2-fluoro-4-yodo-fenilamino)-benzamida para tratar el crecimiento celular anormal en mamíferos y regímenes de dosificacion para la administracion de N-[(R)-2,3-dihidroxi-propoxi]-3,4- difluoro-2-(2-fluoro-4-yodo-fenilamino)-benzamida en mamíferos que padecen cáncer.
ARP050105154A 2004-12-10 2005-12-09 Uso de inhibidores de mek en el tratamiento del crecimiento celular anormal AR052804A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US63514904P 2004-12-10 2004-12-10
US64897205P 2005-01-31 2005-01-31
US68085405P 2005-05-12 2005-05-12
US70831105P 2005-08-15 2005-08-15

Publications (1)

Publication Number Publication Date
AR052804A1 true AR052804A1 (es) 2007-04-04

Family

ID=36353318

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050105154A AR052804A1 (es) 2004-12-10 2005-12-09 Uso de inhibidores de mek en el tratamiento del crecimiento celular anormal

Country Status (4)

Country Link
US (1) US20060154990A1 (es)
AR (1) AR052804A1 (es)
TW (1) TW200633693A (es)
WO (1) WO2006061712A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ567140A (en) 2005-10-07 2011-09-30 Exelixis Inc Azetidines as MEK inhibitors for the treatment of proliferative diseases
CN105106199A (zh) 2006-12-14 2015-12-02 埃克塞利希斯股份有限公司 使用mek抑制剂的方法
WO2008124085A2 (en) * 2007-04-03 2008-10-16 Exelixis, Inc. Methods of using combinations of mek and jak-2 inhibitors
WO2009094211A1 (en) * 2008-01-22 2009-07-30 Concert Pharmaceuticals Inc. Quinazoline compounds and methods of treating cancer
US9205086B2 (en) 2010-04-19 2015-12-08 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
WO2012162293A1 (en) * 2011-05-23 2012-11-29 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mek inhibitors
US20140286902A1 (en) 2011-11-02 2014-09-25 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with platinum-containing agents
EP2773345A1 (en) 2011-11-02 2014-09-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
CA2854188A1 (en) 2011-11-14 2013-05-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
NZ706723A (en) 2012-10-12 2018-07-27 Exelixis Inc Novel process for making compounds for use in the treatment of cancer
JP6863742B2 (ja) * 2013-09-11 2021-04-21 ジ・アドミニストレーターズ・オブ・ザ・チューレーン・エデュケーショナル・ファンド 新規アントラニルアミドとその使用
DK3091981T3 (da) * 2014-01-09 2021-05-31 Verastem Inc Sammensætninger og fremgangsmåder til behandling af abnorm cellevækst
JP2017214291A (ja) * 2014-10-09 2017-12-07 国立大学法人 宮崎大学 骨髄線維化の抑制剤
BR112020013915A2 (pt) * 2018-01-08 2020-12-01 G1 Therapeutics, Inc. regime de dosagem para liberação, e, método para tratar um câncer dependente de replicação de cdk4/6 em um humano
WO2020247275A2 (en) * 2019-06-03 2020-12-10 Sanford Burnham Prebys Medical Discovery Institute Uses of synthetic lethal partners for treatment of cancer
BR112022009390A2 (pt) 2019-11-14 2022-08-09 Amgen Inc Síntese melhorada de composto inibidor de kras g12c
US11571402B2 (en) 2021-02-17 2023-02-07 Springworks Therapeutics, Inc. Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
US11066358B1 (en) 2021-02-17 2021-07-20 Warner-Lambert Company Llc Compositions of essentially pure form IV of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
US11084780B1 (en) 2021-02-17 2021-08-10 Springworks Therapeutics, Inc. Crystalline solids of MEK inhibitor N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
JP2024521788A (ja) 2021-05-27 2024-06-04 ミラティ セラピューティクス， インコーポレイテッド 併用療法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851526A (en) * 1985-04-19 1998-12-22 Ludwig Institute For Cancer Research Methods of treating colon cancer utilizing tumor-specific antibodies
US4956453A (en) * 1985-12-06 1990-09-11 Cetus Corporation Anti-human ovarian cancer immunotoxins and methods of use thereof
US6080751A (en) * 1992-01-14 2000-06-27 The Stehlin Foundation For Cancer Research Method for treating pancreatic cancer in humans with water-insoluble S-camptothecin of the closed lactone ring form and derivatives thereof
EP0692252B1 (en) * 1994-06-14 2001-04-04 "Raffinerie Tirlemontoise", société anonyme: Use of a composition containing inulin or oligofructose in cancer treatment
US6730665B1 (en) * 1999-05-12 2004-05-04 Mayo Foundation For Medical Education And Research Treatment of bone cancer
CN1219753C (zh) * 2000-07-19 2005-09-21 沃尼尔·朗伯公司 4－碘苯氨基苯氧肟酸的氧合酯
IL149462A0 (en) * 2001-05-09 2002-11-10 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
BR0316238A (pt) * 2002-11-15 2005-10-11 Warner Lambert Co Quimioterapia de associação compreendendo um inibidor de mek e capecitabina para tratamento de câncer
CA2542210A1 (en) * 2003-10-21 2005-05-06 Warner-Lambert Company Llc Polymorphic form of n-[(r)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide
WO2005046665A1 (en) * 2003-11-13 2005-05-26 Warner-Lambert Company Llc Combination chemotherapy comprising a mek inhibitor and a erbb1/2 receptor inhibitor
EP1740184A1 (en) * 2004-03-30 2007-01-10 Pfizer Products Incorporated Combinations of signal transduction inhibitors

Also Published As

Publication number Publication date
US20060154990A1 (en) 2006-07-13
WO2006061712A3 (en) 2006-07-27
TW200633693A (en) 2006-10-01
WO2006061712A2 (en) 2006-06-15

Similar Documents

Publication Publication Date Title
AR052804A1 (es) Uso de inhibidores de mek en el tratamiento del crecimiento celular anormal
ECSP066268A (es) Inhibidores de la miostatina (gdf8) en combinación con corticoesteroides para el tratamiento de desórdenes neuromusculares
Irving et al. NGX-4010, a capsaicin 8% dermal patch, administered alone or in combination with systemic neuropathic pain medications, reduces pain in patients with postherpetic neuralgia
CL2016002589A1 (es) Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348).
EA200800006A1 (ru) Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i
BRPI0408902A (pt) composições de inibidores seletivos da ciclooxigenase-2 e agonistas de 5-ht 1b/1d para o tratamento e a prevenção de enxaqueca
GT200300245A (es) Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular
NO20063620L (no) Arylanilinderivater som beta2 adrenergiske receptoragonister
BRPI0414581C1 (pt) composto, composição farmacêutica compreendendo o referido composto e uso do referido composto
ECSP099436A (es) Acilaminopirazoles como inhibidores de fgfr
BRPI0417072A (pt) agente preventivo para a vasculite
BRPI0714399B8 (pt) composição farmacêutica líquida oral
NZ599464A (en) Combination therapies using hdac inhibitors
CR9392A (es) O-desmethylvenlafaxine and bazedoxifene combination product and uses thereof
DOP2010000134A (es) Algunos derivados de 2-pirazinona como inhibidores de elastasa de los neutrofilos
MX2021010321A (es) Compuestos macrociclicos.
CL2007002381A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno susu sales, solvatos o isomeros y uso de la combinacion con al menos un compuesto seleccionado entre diclofenaco, un corticosteroide, un antibiotico, un analgesico, un inmunomodulador, entre otros, para el tratamiento o profilaxis de la dermatitis
UY28255A1 (es) Formas de dosificacion y procedimientos de tratamiento que usan inhibidores del veger
CL2011002233A1 (es) Metodo para tratar o prevenir el cancer, que comprende administrar una combinacion farmaceutica sinergica de: a) (s)-n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)-6-metoxifenil)-1-(2,3-dihidroxipropil)ciclopropan-1-sulfonamida y b) 3-(6,7-bis(2-metoxietoxi)quinazolin-4-ilamino)benzonitrilo; composicion farmaceutica; y kit farmaceutico.
MX2023014563A (es) Combinacion de un inhibidor de braf particular (interruptor de paradoja) y un antagonista de union al eje de pd-1 para su uso en el tratamiento de cancer.
NO20053042L (no) Anvendelse av spongosin (2-metoksyadenosin) for behandling av smerte, saerlig hyperalgesi.
AR044452A1 (es) Combinacion de un antagonista del receptor p2x7 y un inhibidor del factor de necrosis tumoral alfa
DOP2010000197A (es) Derivados de oxindol sustituidos y uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina
CL2008001477A1 (es) Composicion farmaceutica compuesta por la combinacion sinergica de un agente anticonvulsivante como gabapentina y un agente antiinflamatorio no esteroideo como meloxicam, los rangos de concentracion presentes para la gabapentina son 3 a 300 mg y de 0,1 a 30 mg para meloxicam; y uso para tratar el dolor neuropatico
AR080933A1 (es) Tratamiento de esclerosis multiple con masitinib

Legal Events

Date Code Title Description
FB Suspension of granting procedure